CARM
Price
$0.40
Change
-$0.00 (-0.00%)
Updated
Jul 10 closing price
Capitalization
16.63M
PRME
Price
$4.68
Change
+$0.14 (+3.08%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
596.08M
26 days until earnings call
Interact to see
Advertisement

CARM vs PRME

Header iconCARM vs PRME Comparison
Open Charts CARM vs PRMEBanner chart's image
Carisma Therapeutics
Price$0.40
Change-$0.00 (-0.00%)
Volume$360.87K
Capitalization16.63M
Prime Medicine
Price$4.68
Change+$0.14 (+3.08%)
Volume$196.07K
Capitalization596.08M
CARM vs PRME Comparison Chart in %
Loading...
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARM vs. PRME commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Hold and PRME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (CARM: $0.40 vs. PRME: $4.69)
Brand notoriety: CARM and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 2% vs. PRME: 172%
Market capitalization -- CARM: $16.63M vs. PRME: $596.08M
CARM [@Biotechnology] is valued at $16.63M. PRME’s [@Biotechnology] market capitalization is $596.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than CARM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • CARM’s TA Score: 5 bullish, 5 bearish.
  • PRME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CARM and PRME are a good buy in the short-term.

Price Growth

CARM (@Biotechnology) experienced а -1.24% price change this week, while PRME (@Biotechnology) price change was +50.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

CARM is expected to report earnings on May 13, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($596M) has a higher market cap than CARM($16.6M). PRME YTD gains are higher at: 60.616 vs. CARM (-4.967). CARM has higher annual earnings (EBITDA): -49.68M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. CARM (7.74M). CARM has less debt than PRME: CARM (2.33M) vs PRME (121M). CARM has higher revenues than PRME: CARM (20M) vs PRME (3.85M).
CARMPRMECARM / PRME
Capitalization16.6M596M3%
EBITDA-49.68M-200M25%
Gain YTD-4.96760.616-8%
P/E RatioN/AN/A-
Revenue20M3.85M520%
Total Cash7.74M144M5%
Total Debt2.33M121M2%
FUNDAMENTALS RATINGS
CARM vs PRME: Fundamental Ratings
CARM
PRME
OUTLOOK RATING
1..100
9233
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3734
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (62) in the null industry is in the same range as CARM (93). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as CARM (100). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's SMR Rating (98) in the null industry is in the same range as CARM (100). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's Price Growth Rating (34) in the null industry is in the same range as CARM (37). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as CARM (100). This means that PRME’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMPRME
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 9 days ago
85%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 29 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CARM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TOCQX50.61N/A
N/A
Tocqueville
GSROX14.44N/A
N/A
Goldman Sachs Small Cap Gr Insghts R
JIGTX32.80N/A
N/A
JHancock International Growth R6
RRSVX15.25N/A
N/A
RBC Small Cap Value R6
GMOWX18.78N/A
N/A
GMO Resources VI

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with EVGN. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then EVGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
N/A
EVGN - CARM
60%
Loosely correlated
-2.68%
INSM - CARM
40%
Loosely correlated
+0.20%
PMVP - CARM
34%
Loosely correlated
-1.55%
ABCL - CARM
31%
Poorly correlated
+9.25%
VCYT - CARM
31%
Poorly correlated
+3.54%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+3.30%
CRSP - PRME
63%
Loosely correlated
-1.80%
BEAM - PRME
58%
Loosely correlated
+2.66%
RXRX - PRME
56%
Loosely correlated
+2.24%
CRBU - PRME
52%
Loosely correlated
-0.57%
CCCC - PRME
51%
Loosely correlated
-1.49%
More